Bayer's Regulatory Calendar: A Farm Study, a Drug Filing and a Quarter That Has Yet to Report
Published on 10/16/2026 at 13:31 | Editorial boerse-global.de
Two regulatory developments and one looming quarterly report give Bayer investors plenty to weigh this autumn — though each item belongs in a different column of the ledger.
On the agricultural side, Bayer is pressing Brussels and Westminster for a more innovation-friendly rulebook, leaning on a study published yesterday by Oxford Economics. Commissioned by the company itself, the research warns that the EU and the UK risk sliding further behind in global agricultural competition. The finding is best read as context for the sector's headwinds rather than as evidence of a turnaround in Bayer's crop science business.
A slow-growth statistic with a political purpose
Between 2011 and 2023, arable farming in the EU expanded by an average of just 0.1 percent a year, according to the study — a pace that trails key agricultural markets elsewhere. Bayer ties that figure to its call for faster access to innovation, aiming its message not only at shareholders but at regulators as well.
The identity of the sponsor matters when interpreting the numbers. Because Oxford Economics produced the analysis on Bayer's behalf, it functions as ammunition for the company's lobbying position. Nothing in its findings about European arable output translates directly into an improved outlook for Bayer's own earnings. That distinction — between an industry diagnosis and a company's trajectory — is the crux. The study documents a long-term competitiveness problem; it does not answer how quickly Bayer can close the well-documented gap in its agricultural division.
Should investors sell immediately? Or is it worth buying Bayer?
UBS stays bullish, with an eye on the pharma pipeline
Analysts, for their part, are looking elsewhere. On Wednesday, UBS reaffirmed its buy rating and a price target of 62 euros. Analyst Matthew Weston called the weakness in the crop science unit a known quantity and said the trends for 2026 and 2027 should remain intact. His focus sits on the pharmaceutical side, where UBS expects sustained momentum — with the US approval of Asundexian as the key catalyst.
That view places a different emphasis than the Oxford Economics paper: for the share price, the company's own operating performance counts alongside the regulatory environment. Investors will get a chance to test those expectations on 3 November, when Bayer reports third-quarter 2026 results.
Finerenone clears a procedural hurdle in the US
The pharma story has already produced fresh headlines. On 8 October, Bayer disclosed that the US Food and Drug Administration has accepted its supplemental application for finerenone, marketed as Kerendia, covering adults with chronic kidney disease without diabetes. The filing rests on the Phase III FIND-CKD trial.
Acceptance, however, is a procedural step — not a decision on the sought-after label expansion. Bayer has cleared another regulatory stage, but the outcome remains open. A separate German decision concerns the same active ingredient in a different indication, heart failure, while the US proceeding targets chronic kidney disease without diabetes. Same molecule, different patient populations, different regulatory tracks.
Bayer is also putting money behind its manufacturing footprint. On 2 October, the company announced plans to invest 2.2 billion US dollars in a new pharmaceutical production site in New Albany, Ohio, expected to create roughly 600 jobs.
Bayer at a turning point? This analysis reveals what investors need to know now.
Legal overhangs keep the optimism in check
Those advances must be set against substantial legal risks. According to media reports on Wednesday, the 7.25 billion US dollar glyphosate settlement had not yet been approved, and a glyphosate trial that began in Missouri in late September was cited as an additional burden. An EPA assessment of glyphosate is expected toward the end of 2026.
The finerenone news does not make any of those uncertainties disappear. What it does provide is a standalone positive element for assessing the operating business — progress on a drug, set against unresolved legal questions. For investors, the takeaway is to judge the two developments separately. The agricultural study broadens the explanation for a difficult industry environment, but it offers no all-clear for Bayer's crop business. The next hard test remains the operating report on 3 November, not the political appeal for friendlier innovation rules.
Ad
Bayer Stock: New Analysis - 16 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
